Validating cell surface proteases as drug targets for cancer therapy : what do we know, and where do we go?

Bron
Cancers - ISSN 2072-6694-14:3 (2022) p.
Auteur(s)

Profiling of proteases as potential therapeutic targets : focus on inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)

Bron
Antwerpen, Universiteit Antwerpen, Faculteit Farmaceutische, Biomedische en Diergeneeskundige Wetenschappen, Departement Farmaceutische Wetenschappen, 2022,ix, 259 p.
Auteur(s)

Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics : a step to improve tumor uptake and retention time

Bron
American journal of nuclear medicine and molecular imaging - ISSN 2160-8407-11:6 (2021) p. 476-+
Auteur(s)

The chemokine-based peptide, CXCL9(74-103), inhibits angiogenesis by blocking heparan sulfate proteoglycan-mediated signaling of multiple endothelial growth factors

Bron
Cancers - ISSN 2072-6694-13:20 (2021) p.
Auteur(s)
    Alexandra De Zutter, Helena Crijns, Nele Berghmans, Melissa Garcia-Caballero, Lotte Vanbrabant, Noemie Poertner, Vincent Vanheule, Paulien Verscheure, Mohammad Mairaj Siddiquei, Ahmed M. Abu El-Asrar, Peter Carmeliet, Pieter Van Wielendaele, Ingrid De Meester, Jo Van Damme, Paul Proost, Sofie Struyf